• Olha Chyniak Department of Neurosurgery and Neurology, Medical institute, Sumy State University, Sumy, Ukraine
  • Olga Dubenko Department of Neurology and Neurosurgery, Kharkiv Medical Academy of Postgraduate Education, Kharkiv, Ukraine
  • Olexander Potapov Department of Neurosurgery and Neurology, Medical Institute, Sumy State University, Sumy, Ukraine
  • Anastasia Shulga 5th–year student, Medical Institute, Sumy State University, Sumy, Ukraine
  • Anastasia Kotsyuba 5th–year student, Medical Institute, Sumy State University, Sumy, Ukraine
Keywords: Parkinson's disease, treatment, levadopa, Sinemet, α synuclein, deep brain stimulation, immunotherapy


Introduction. Parkinson's disease (PD) is a neurodegenerative neurological disease with a slowly progressive course. In particular, it manifests as a movement disorder that includes rest tremor, rigidity, bradykinesia, and postural instability. Movement disorder in patients with PD mainly occurs due to the selective loss of pigmented dopaminergic neurons of the compact area of the substantia nigra, as a result of the depletion of dopamine in the striatum. The pathogenetic feature of this disease is the presence of intraneuronal aggregates and inclusions of α-synuclein. To date, there are no proven treatments for Parkinson's disease, but a number of medications exist offering benefits in terms of controlling movement disorders. Although they can significantly improve motor function, they can also lead to problematic side effects, especially as the disease progresses.

Objective: to analyze the main directions of modern methods of Parkinson's disease treatment and to conduct a profound review and analysis of literature research data on the modern methods of Parkinson's disease treatment over the past 10 years.

Results. It has been established that modern treatment methods are based mainly on exogenous administration of drugs with dopaminergic activity and inhibitors of endogenous dopamine metabolism. Although levodopa has been used in the treatment of Parkinson's disease since its inception, numerous experimental therapeutic and neurosurgical approaches are now being investigated. These include drugs aiming at the inhibition and degradation of α-synuclein aggregation, which is considered the driving force of neurodegeneration in Parkinson's disease. They raise expectations that a disease-modifying agent will be discovered in the short-term future. Thus, in combination with a number of regenerative and neurosurgical approaches, including stem cell and gene therapy and deep brain stimulation, significant progress will be made in the treatment of Parkinson's disease in the coming years and a number of new effective options will become available.


Download data is not yet available.


Kalia LV, Lang AE: Parkinson's disease. Lancet. 2015;386(9996):896–912.–6736(14)61393–3.

Keener AM, Bordelon YM. Parkinsonism. Semin Neurol. 2016;36(4):330–4. https://doi:10.1055/s–0036–1585097.

Campbell MC, Myers PS, Weigand AJ, Foster ER, Cairns NJ, Jackson JJ, Lessov–Schlaggar CN, Perlmutter JS. Parkinson disease clinical subtypes: key features & clinical milestones. Ann Clin Transl Neurol. 2020;7(8):1272–1283. https://doi.10.1002/acn3.51102.

Tang Y, Xiao X, Xie H, Wan CM, Meng L, Liu ZH, Liao WH, Tang BS, Guo JF. Altered Functional Brain Connectomes between Sporadic and Familial Parkinson's Patients. Front Neuroanat. 2017;11:99. https://doi:10.3389/fnana.2017.00099.

Kluss J, Mamais A, Cookson M. LRRK2 links genetic and sporadic Parkinson’s disease. Biochem Soc Trans. 2019; 47(2): 651–661.

Huot P, Johnston TH, Koprich JB, et al.: The pharmacology of L–DOPA–induced dyskinesia in Parkinson's disease. Pharmacol Rev. 2013;65(1):171–222.

Mayo Clinic. 2018. Available from.–supplements/levodopa–oral–route/proper–use/drg–20064498.

Nord M. Linköping: Linköping University Electronic Press. Levodopa pharmacokinetics–from stomach to brain: A study on patients with Parkinson’s disease. 2017;1–72.

Borovac JA. Side effects of a dopamine agonist therapy for Parkinson's disease: a mini–review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37–47. PMID: 27505015.

Williams–Gray CH, Mason SL, Evans JR, et al.: The CamPaIGN study of Parkinson's disease: 10–year outlook in an incident population–based cohort. J Neurol Neurosurg Psychiatr. 2013;84(11):1258–64.–2013–305277.

Konovalova E et al. Mutations in the Parkinson’s Disease–Associated PARK2 Gene Are Accompanied by Imbalance in Programmed Cell Death Systems. Acta Naturae. 2015; 7(4): 146–149. PMCID: PMC4717261.

Lauren K et al. Solving neurodegeneration: common mechanisms and strategies for new treatments. Mol Neurodegener. 2022;17(1):23.–022–00524–0.

Kim HJ, Mason S, Foltynie T, et al.: Motor complications in Parkinson's disease: 13–year follow–up of the CamPaIGN cohort. Mov Disord. 2020;35(1):185–90.

Carbone F, Djamshidian A, Seppi K, Poewe W. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019;33(9):905–918.–019–00661–z.

Oertel WH. Recent advances in treating Parkinson's disease. F1000Res. 2017;6:260.

Scott NW, Macleod AD, Counsell CE. Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol. 2016;23: 304–12.

Zhang PL, Wang YX, Chen Y, Zhang CH, Li CH. The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease. Exp Ther Med. 2018;15(1):127–130. https://doi:10.3892/etm.2017.5377.

Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L. Safety and efficacy of tolcapone in Parkinson's disease: systematic review. Eur J Clin Pharmacol. 2021;77(6):817–829. https://doi:10.1007/s00228–020–03081–x.

Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta–analysis. Neurol Sci. 2020;41(8):2045–2054. https://doi:10.1007/s10072–020–04303–x.

Borovac JA. Side effects of a dopamine agonist therapy for Parkinson's disease: a mini–review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37–47.PMID: 27505015; PMCID: PMC4797835.

Stathis P, Konitsiotis S, Antonini A. Dopamine agonists early monotherapy for the delay of development of levodopa–induced dyskinesias. Expert Rev Neurother. 2015;15(2):207–13. https:// doi:10.1586/14737175.2015.1001747.

Zhu J, Chen M. The effect and safety of ropinirole in the treatment of Parkinson disease: A systematic review and meta–analysis. Medicine (Baltimore).2021;100(46):e27653. https:// doi:10.1097/MD.0000000000027653.

Nyholm D, Jost WH. Levodopa–entacapone–carbidopa intestinal gel infusion in advanced Parkinson's disease: real–world experience and practical guidance. Ther Adv Neurol Disord. 2022;15:17562864221108018. https://doi:10.1177/17562864221108018.

Ruan X, Lin F, Wu D, Chen L, Weng H, Yu J, Wang Y, Chen Y, Chen X, Ye Q, Meng F, Cai G. Comparative Efficacy and Safety of Dopamine Agonists in Advanced Parkinson's Disease With Motor Fluctuations: A Systematic Review and Network Meta–Analysis of Double–Blind Randomized Controlled Trials. Front Neurosci. 2021;15:728083. https://doi:10.3389/fnins.2021.728083.

Frampton JE. Rotigotine Transdermal Patch: A Review in Parkinson's Disease. CNS Drugs. 2019;33(7):707–718. https://doi:10.1007/s40263–019–00646–y.

Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics. 2013;13(2):103–7. https://doi:10.1111/j.1479–8301.2012.00432.x.

Armstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548–560. https://doi:10.1001/jama.2019.22360.

Ntetsika T, Papathoma PE, Markaki I. Novel targeted therapies for Parkinson's disease. Mol Med. 2021;27(1):17. https://doi:10.1186/s10020–021–00279–2.

Palfi et al. Long–term safety and tolerability of ProSavin, a lentiviral vector–based gene therapy for Parkinson's disease: a dose escalation, open–label, phase 1/2 trial. Lancet. 2014;383(9923):1138–46. https://10.1016/S0140–6736(13)61939–X.

Brot S, Thamrin NP, Bonnet ML, Francheteau M, Patrigeon M, Belnoue L, Gaillard A. Long–Term Evaluation of Intranigral Transplantation of Human iPSC–Derived Dopamine Neurons in a Parkinson's Disease Mouse Model. Cells. 2022;11(10):1596. https://doi:10.3390/cells11101596.

Amanda MT, Stephanie J, Heflin, Arlene A. Hirano, Nicholas C. Brecha, and Vadim Y. Arshavsky. Dopamine–dependent sensitization of rod bipolar cells by gaba is conveyed through wide–field amacrine cells. J. of Neuroscience.2018; 38(3):723–732.

Ásgrímsdóttir ES and Arenas E. Midbrain Dopaminergic Neuron Development at the Single Cell Level: In vivo and in Stem Cells. Front. Cell Dev. Biol. 2020; 8:463. https://doi:10.3389/fcell.2020.00463

Mittal S, Bjørnevik K, Im DS, Flierl A, Dong X, Locascio JJ, Abo KM, Long E, Jin M, Xu B, Xiang YK, Rochet JC, Engeland A, Rizzu P, Heutink P, Bartels T, Selkoe DJ, Caldarone BJ, Glicksman MA, Khurana V, Schüle B, Park DS, Riise T, Scherzer CR. β2–Adrenoreceptor is a regulator of the α–synuclein gene driving risk of Parkinson's disease. Science. 2017;357(6354):891–898. https://doi:10.1126/science.aaf3934.

George S, Brundin P. Immunotherapy in Parkinson's Disease: Micromanaging Alpha–Synuclein Aggregation. J Parkinsons Dis. 2015;5(3):413–24. https:// doi:10.3233/JPD–150630.

Decressac M, Mattsson B, Weikop P, Lundblad M, Jakobsson J, Björklund A. TFEB–mediated autophagy rescues midbrain dopamine neurons from α–synuclein toxicity. Proc Natl Acad Sci U S A. 2013;110(19):E1817–26. https://doi:10.1073/pnas.1305623110.

Smith L, Schapira AHV. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells. 2022;11(8):1261. https://doi:10.3390/cells11081261.

Khalifeh M, Barreto GE, Sahebkar A. Trehalose as a promising therapeutic candidate for the treatment of Parkinson's disease. Br J Pharmacol. 2019;176(9):1173–1189. https://doi:10.1111/bph.14623.

Karen Castillo, Melissa Nassif, Vicente Valenzuela, Fabiola Rojas, Soledad Matus, Gabriela Mercado, Felipe A. Court, Brigitte van Zundert & Claudio Hetz (2013) Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in motoneurons, Autophagy, 9:9, 1308–1320, https://doi:10.4161/auto.25188

Kalia SK, Sankar T, Lozano AM. Deep brain stimulation for Parkinson's disease and other movement disorders. Curr Opin Neurol. 2013;26(4):374–80. https://doi:10.1097/WCO.0b013e3283632d08є.

Hacker ML, DeLong MR, Turchan M, Heusinkveld LE, Ostrem JL, Molinari AL, Currie AD, Konrad PE, Davis TL, Phibbs FT, Hedera P, Cannard KR, Drye LT, Sternberg AL, Shade DM, Tonascia J, Charles D. Effects of deep brain stimulation on rest tremor progression in early stage Parkinson disease. Neurology. 2018;91(5):e463–e471. https://doi:10.1212/WNL.000000000000590.

Okun MS. Deep–brain stimulation––entering the era of human neural–network modulation. N Engl J Med. 2014;371(15):1369–73. https://doi:10.1056/NEJMp1408779.

Malek N. Deep Brain Stimulation in Parkinson's Disease. Neurol India. 2019;67(4):968–978. https://doi:10.4103/0028–3886.266268.

How to Cite
Olha Chyniak, Olga Dubenko, Olexander Potapov, Anastasia Shulga, & Anastasia Kotsyuba. (2023). PARKINSON’S DISEASE — OVERVIEW OF MODERN TREATMENT METHODS. East Ukr Med J, 11(1), 1-13.;11(1):1-13